TSO3 — Investor Presentation (May 2017)
31 slides from TSO3's investor presentation, May 2017
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
TSX:TOS To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation May 2017
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certa
Slide 3: TSO3 - Our Vision
TSO3 - Our Vision TSX:TOS To Create and Deliver the New Standard of Care in Sterile Reprocessing™ 3
Slide 4: Company Milestones
Company Milestones TSX:TOS 2016 Shipped 110 STERIZONE® VP4 Sterilizers Secured significant P.O. for 2017 shipments 2009 - 2014 Record revenues & assembly capacity Reworked products US$19.6M in cash1 1998 Introduced STERIZONE® Extended FDA claims to include 125L+ and VP4 Sterilizers col
Slide 5: Purpose
Purpose TSX:TOS A Sterile Device for Every Procedure 5
Slide 6: The Science – Patents or Patents Pending
The Science – 47 Patents or Patents Pending TSX:TOS Half-Cycle 1 Half-Cycle 2 Pressure 1000 (Torr) Atmosphere 100 20 10 1 Dynamic Dynamic H2O2 H2O2 Time Exposure Exposure Pre- H2O2 Evacuation H2O2 Evacuation Ventilation conditioning Reduction Reduction Phase 1 Phase 2 6
Slide 7: Create and Control a Micro-Condensation Event
Create and Control a Micro-Condensation Event TSX:TOS Dynamic Delivery System™ A relatively cool device in a warm humid environment 7
Slide 8: Central Sterilization (OR Support)
Central Sterilization (OR Support) 8
Slide 9: Existing Sterilization Equipment Market
Existing Sterilization Equipment Market TSX:TOS Global Sterilization Equipment Market3 LT Sterilization is fastest growing ($ billions) sterilization segment (9-10% CAGR)1 $6.9B Estimated equipment replacement value $6.4B $5.9B approximately $4.5 billion2 $5.5B $5.1B $4.7B ~30,000 units global
Slide 10: Growing Demand for MIS & Endoscopy Procedures
Growing Demand for MIS & Endoscopy Procedures TSX:TOS Aging Recovery Bed Time Minimally Invasive Surgeries Population Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries & Endoscopies Growth in U.S. Population Age Groups 65+2 More than 30 million 85+ MIS procedur
Slide 11: STERIZONE VP4 Sterilizer
STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim - Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free Proprietary Technology automatically cycle selection adjusts the st
Slide 12: Improving Existing LT Sterilization Practice
Improving Existing LT Sterilization Practice TSX:TOS Old Technology TSO3 Technology • 20+ year-old core technology Next generation industry technology • Single sterilant Dual Sterilant • Fixed delivery Dynamic Delivery • Time consuming, complex procedures Simple Single Cycle Operation • Oper
Slide 13: Chamber Load Capacities
Chamber Load Capacities TSX:TOS Competitive Comparison of a Typical Flexible Endoscope Load VS 13
Slide 14: GI Market
GI Market +, 14
Slide 15: GI Endoscopy Market
GI Endoscopy Market TSX:TOS Greenfield opportunity for Terminal Endoscopic Procedures in Europe and US1,2 Sterilization – displacing HLD (millions) Potential to terminally sterilize far more of 75M the 55m+ annual endoscopies1 (US & Europe) 55M Nearly 50% are colonoscopies – none of which are
Slide 16: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing TSX:TOS Old Technology TSO3 Technology • Typically high level disinfection Sterilization not high level disinfection • A fundamentally inferior level of Far higher degree of certainty certainty • Many contaminated scopes The only FDA-cleared technology val
Slide 17: The Problem: Endoscopes & Superbugs
The Problem: Endoscopes & Superbugs TSX:TOS SUPERBUG = Antimicrobial Resistant Bacteria 2 million+ Americans suffer from antibiotic-resistant bacteria annually – 23,000 die1 CRE is resistant to most available antibiotics - up to 50% of infected patients die2 CRE infections growing and linked
Slide 18: Call to Action
Call to Action TSX:TOS “Despite reprocessing in accordance with US guidelines, viable microbes and Portion of Gastroscopes Meeting biologic debris persisted in clinically used [GI] endoscopes, suggesting current Cleaning Benchmarks reprocessing guidelines are not sufficient to ensure successful deco
Slide 19: The Solution: FDA Clearance of Endoscope Claims
The Solution: FDA Clearance of Endoscope Claims TSX:TOS CLEARED An Industry First: FDA has cleared the STERIZONE® VP4 Sterilizer for the sterilization of multi-channeled flexible endoscopes (with four or fewer channels) having internal lumens of ≥ 1.45 mm in July 2016: FDA cleared expanded indicatio
Slide 20: Next Steps: the GI Market
Next Steps: the GI Market TSX:TOS Duodenoscope Expanded Claims – FDA – Duodenoscopes Already cleared in Canada and Europe Duodenoscope internal testing complete Initiated testing with key ERCP OEM Market/Industry Awareness – All Flexible Scopes Working with US legislators on awareness ca
Slide 21: Commercialization
Commercialization 21
Slide 22: Commercialization
Commercialization TSX:TOS “The STERIZONE® VP4 Sterilizer Getinge: Exclusive Global Distributor uniquely addresses an unmet global Global sales & service - over 3,000 associates in 36 countries need for cost effective, high throughput US$7.5M up front license fee sterilization of complex medica
Slide 23: Commercialization
Commercialization TSX:TOS Overview Brochure Fractional Print Ad Series Email /Mobile Email Landing Page Web Banners 23
Slide 24: Commercialization
Commercialization TSX:TOS Fractional Print Ad Series 24
Slide 25: IAHCSMM, Nashville - May 2017
IAHCSMM, Nashville - May 2017 TSX:TOS 25
Slide 26: 2016 and 2017 Financial Highlights – USD
2016 and 2017 Financial Highlights – USD TSX:TOS Quarterly Revenues 2016 and 2017 Highlights US$ Millions $4.2 2016 Revenues: $13.3M (110 units shipped) $3.7 Q1 2017 Revenues: $4.2M (36 units shipped) $3.5 $3.1 $3.0 Q1 2017 Gross margin: 37% Installations occurring and consumables sales gr
Slide 27: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) All dollars in USD, unless noted otherwise TSX:TOS Stock Price (5/3/17) CAD$3.15 Total Revenue (mrq) $4.2M Cash & ST Investments (mrq) $19.6M 52 Week High-Low CAD$3.82-$2.05 Gross Profit (mrq) $1.6M Total Assets (mrq) $26.7M Avg. Daily Vol. (3 mo.) 0.15M Net Loss (mrq) $(2.0)M T
Slide 28: TSO3 Key Takeaways
TSO3 Key Takeaways TSX:TOS Recurring Revenue Business Model with proprietary captive Global consumables Distribution Partner Industry Changing Technology Dual Sterilant Dynamic Sterilant Delivery SystemTM Addressing Large Market Opportunities Traditional low temperature sterilization F
Slide 29: Contact Us
Contact Us TSX:TOS TSO3 Inc. - Canada Investor Relations 2505 Dalton Avenue Québec, Québec Ron Both Managing Partner G1P 3S5 CANADA CMA Tel (949) 432-7566 Tel (418) 651-0003 TOS@cma.team info@tso3.com Barry Mire Vice President TSO3 Corporation - US Renmark Financial Communications Inc. Tel (416) 644
Slide 30: Appendix
Appendix +,
Slide 31: Regulatory Progression - Endoscopes
Regulatory Progression - Endoscopes TSX:TOS FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi-Critical Critica